Is methionine oxidation reversible?

In cells, yes — methionine sulfoxide reductases reduce it back, which is unusual among oxidative modifications.

How does that make it an antioxidant?

Preferential oxidation intercepts oxidants that would otherwise damage residues permanently, and the reductases regenerate the capacity.

Does this change storage advice?

No. A vial has no reductases, so oxidation there is one-way and cumulative. The functional role applies inside a living system.

MOTS-c (Mitochondrial Peptide)

The Residue That Oxidises So Others Do Not

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Methionine oxidises readily to the sulfoxide, which is normally described as degradation. Uniquely among common oxidative modifications it is enzymatically reversible, so methionine can absorb oxidative insult repeatedly — functioning as a regenerable buffer rather than simply being damaged.

Key facts

Oxidation product: Methionine sulfoxide, +16 Da
Unusual property: Enzymatically reversible
Reducing enzymes: Methionine sulfoxide reductases
Consequence: Repeatable, not one-way
Proposed role: Antioxidant buffer
Key paper: Bender 2008, PNAS (PMID 18946048)

Why most oxidative damage is permanent

Oxidation of most amino acid side chains produces products the cell cannot undo. Carbonylation of lysine or arginine, oxidation of tryptophan, cleavage of the peptide backbone — these are terminal, and the only remedy is degrading the protein and building another. Damage of that kind accumulates.

Why methionine is different

Its thioether sulfur oxidises to the sulfoxide, and cells possess methionine sulfoxide reductases that reduce it back. That makes the modification a cycle rather than an endpoint. A methionine residue can be oxidised, restored and oxidised again, which is a fundamentally different relationship with reactive oxygen than any residue that is simply destroyed.

Research material referenced

MOTS-C 10mg — third-party HPLC tested

View — £24.99

How that becomes a defence

If methionine is preferentially oxidised, it intercepts oxidants that would otherwise reach residues where damage is permanent. Surface methionines effectively act as a sacrificial layer, and because the reductases restore them, the protective capacity regenerates rather than depleting. The residue is doing work by being vulnerable.

The argument Bender and colleagues made

That mitochondria increased methionine content deliberately, through the genetic code itself. Their 2008 PNAS paper argues adaptive antioxidant methionine accumulation in respiratory chain complexes explains why mitochondria use a deviant code — the AUA reassignment substitutes methionine for isoleucine, and the compartment doing so is the one producing the most reactive oxygen.

What this changes about reading a certificate

Nothing about handling: a +16 Da satellite still indicates oxidation, and oxidised material still differs from what was specified. But it reframes why a mitochondrial peptide is methionine-rich in the first place. The residues that make MOTS-c awkward to store are plausibly there for a reason, and vulnerability in a vial is not the same as vulnerability in a cell — a cell has reductases and a vial does not.

Where the analogy stops

Regeneration requires enzymes. A lyophilised peptide in a vial has none, so oxidation there is one-way and cumulative in exactly the way the storage guidance assumes. The functional argument concerns methionine inside a living system; the handling concern concerns methionine in storage. Both are correct and they describe different situations.

Extended research context

The MOTS-c (Mitochondrial Peptide) deep dive

Deep dive: why a peptide encoded in mitochondrial DNA is unusual

The human mitochondrial genome is 16,569 base pairs encoding 37 genes, and was considered fully characterised by the 1980s: thirteen respiratory-chain proteins, twenty-two transfer RNAs, two ribosomal RNAs. MOTS-c is encoded by a short open reading frame nested inside the 12S rRNA gene — sequence already annotated as doing something else, which is exactly why it went unnoticed. Humanin, found in 2001 inside the 16S rRNA gene, established that the genome held more than its annotation suggested; MOTS-c was found in 2015 by looking deliberately. The implication is that the mitochondrion encodes and releases signalling molecules of its own, rather than only executing instructions sent from the nucleus.

Deep dive: AMPK activation without touching AMPK

AMPK is normally activated when AMP and ADP bind its gamma subunit, making it a direct sensor of the AMP-to-ATP ratio. MOTS-c does not raise that ratio and does not bind the kinase. It inhibits the folate cycle, the one-carbon pathway feeding de novo purine biosynthesis, and the intermediate AICAR accumulates as a result. AICAR is an AMP mimetic — phosphorylated to ZMP, it binds the same regulatory site AMP occupies. So the peptide reaches a cytosolic energy sensor through one-carbon metabolism and a diffusible small molecule, which is a materially different architecture from a receptor-ligand interaction, and different again from metformin's inhibition of complex I.

Deep dive: reading a preclinical literature honestly

Roughly 250 indexed papers exist, and the overwhelming majority are cell and rodent studies. Where humans appear, the work is generally observational: measuring circulating concentrations and correlating them with age, fitness or metabolic state. The 2021 Nature Communications paper is the clearest example of the structure — the human arm measured MOTS-c before and after exercise, finding roughly a 12-fold rise in skeletal muscle against 1.6-fold in circulation, while the interventional work was done in mice. Two inferences the secondary literature routinely makes and the primary literature does not support: that a correlation between low concentrations and poor metabolic health establishes direction, and that a molecule which rises during exercise would reproduce exercise if administered.

Research applications

▸Study of mitochondrial-derived peptides and retrograde signalling
▸AMPK pathway research through non-canonical activation
▸One-carbon and folate-cycle metabolism models
▸Exercise physiology and mitochondrial bioenergetics research
▸Ageing biology and mitochondrial genome expression studies

Handling checklist

✓Store lyophilised material cold, dry and protected from light
✓Expect methionine oxidation as the primary degradation route (+16 Da per residue)
✓No reducing agent needed — the sequence contains no cysteine
✓Introduce diluent gently against the vial wall; swirl rather than shake
✓Aliquot to avoid repeated freeze-thaw cycles
✓Check mass spectrometry for +16 and +32 satellites before relying on a batch

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Reading exercise induction as proof that administration mimics exercise

Fix: The papers report that exercise raises MOTS-c. The reverse inference is not supported and is not claimed.

✗ Treating human observational data as interventional evidence

Fix: Human work measures endogenous concentrations; administration studies were conducted in mice.

✗ Assuming MOTS-c has a cell-surface receptor like humanin

Fix: No receptor is established. Its characterised activity is intracellular.

✗ Storing reconstituted material as though it were as stable as the powder

Fix: Solution-phase material is subject to hydrolysis and oxidation; the lyophilised form is far more stable.

✗ Overlooking WADA status in athlete-adjacent research

Fix: MOTS-c is on the prohibited list; this is relevant to any research context involving competitors.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Is methionine oxidation reversible?: In cells, yes — methionine sulfoxide reductases reduce it back, which is unusual among oxidative modifications.
How does that make it an antioxidant?: Preferential oxidation intercepts oxidants that would otherwise damage residues permanently, and the reductases regenerate the capacity.
Does this change storage advice?: No. A vial has no reductases, so oxidation there is one-way and cumulative. The functional role applies inside a living system.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More MOTS-c (Mitochondrial Peptide) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum